Covered recipient · General Payments record
SHEILA MARGARET FULLER
Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner Family
General Payments · PY2021–2024
$858.52
- Reported across 27 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $317.90 | 16 |
| Education | $90.00 | 1 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $117.58 | 6 |
| Astellas Pharma US Inc | $110.81 | 2 |
| Lilly USA, LLC | $40.58 | 2 |
| GlaxoSmithKline, LLC. | $29.86 | 2 |
| ABBVIE INC. | $27.55 | 1 |
| Abbott Laboratories | $23.78 | 1 |
| PFIZER INC. | $20.25 | 1 |
| Amgen Inc. | $19.41 | 1 |
| Axsome Therapeutics, Inc. | $18.08 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $23.78 | 09/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125196779 | CMS |
| ABBVIE INC. | $27.55 | 12/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107137932 | CMS |
| Amgen Inc. | $19.41 | 07/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117255555 | CMS |
| Astellas Pharma US Inc | $20.81 | 01/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139473688 | CMS |
| Astellas Pharma US Inc | $90.00 | 01/23/2024 | Education | Undisputed | 01/23/2026 | 1139528726 | CMS |
| Axsome Therapeutics, Inc. | $18.08 | 03/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148409704 | CMS |
| GlaxoSmithKline, LLC. | $15.56 | 05/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116638348 | CMS |
| GlaxoSmithKline, LLC. | $14.30 | 07/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116686713 | CMS |
| Lilly USA, LLC | $17.58 | 02/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135908539 | CMS |
| Lilly USA, LLC | $23.00 | 05/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135888980 | CMS |
| Novo Nordisk Inc | $18.05 | 02/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100420644 | CMS |
| Novo Nordisk Inc | $24.32 | 05/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100398430 | CMS |
| Novo Nordisk Inc | $22.96 | 06/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100372896 | CMS |
| Novo Nordisk Inc | $15.53 | 06/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100391842 | CMS |
| Novo Nordisk Inc | $21.02 | 09/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100483547 | CMS |
| Novo Nordisk Inc | $15.70 | 10/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100471177 | CMS |
| PFIZER INC. | $20.25 | 10/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132084588 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.